top of page

Swiss Biotech Day: Molecular Partners' CEO and Swiss Biotech Association president Patrick Amstutz shares his take on biotech and previews what to expect from his U.S. listed company in 2025

  • blonca9
  • 5 hours ago
  • 1 min read

He describes the clinical multi-specific T-cell engager program that will have data this year, and highlights the idea behind a next-generation logic-gating platform. Plus, entering the clinic with a DLL3 radio-DARPin and choosing mesothelin as a second target.




Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Allucent logo_tagline.png

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

bottom of page